Recently, Resmetirom (Rezdiffra, Madrigal Pharmaceuticals, Inc), a thyroid hormone receptor-beta (THRβ) agonist was approved for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis [25]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.